Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Shopping guides are about more than just helping you to find the right vehicle. J.D. Power assists you with that, of course, but also answers questions you might have through car shopping, car buying, ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein (a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has ...